MA43055A - Anticorps agonistes se liant de manière spécifique au cd40 humain et procédés d'utilisation - Google Patents

Anticorps agonistes se liant de manière spécifique au cd40 humain et procédés d'utilisation

Info

Publication number
MA43055A
MA43055A MA043055A MA43055A MA43055A MA 43055 A MA43055 A MA 43055A MA 043055 A MA043055 A MA 043055A MA 43055 A MA43055 A MA 43055A MA 43055 A MA43055 A MA 43055A
Authority
MA
Morocco
Prior art keywords
human
methods
specifically binding
antibodies specifically
agonist antibodies
Prior art date
Application number
MA043055A
Other languages
English (en)
Inventor
Johan Fransson
Paul Kim
Michael Quigley
Andressa Smith
Alexey Teplyakov
Hong Zhou
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA43055A publication Critical patent/MA43055A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA043055A 2015-09-30 2016-09-30 Anticorps agonistes se liant de manière spécifique au cd40 humain et procédés d'utilisation MA43055A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562234812P 2015-09-30 2015-09-30

Publications (1)

Publication Number Publication Date
MA43055A true MA43055A (fr) 2018-08-08

Family

ID=58409279

Family Applications (2)

Application Number Title Priority Date Filing Date
MA043053A MA43053A (fr) 2015-09-30 2016-09-30 Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation
MA043055A MA43055A (fr) 2015-09-30 2016-09-30 Anticorps agonistes se liant de manière spécifique au cd40 humain et procédés d'utilisation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA043053A MA43053A (fr) 2015-09-30 2016-09-30 Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation

Country Status (23)

Country Link
US (2) US20190048089A1 (fr)
EP (2) EP3356532B1 (fr)
JP (2) JP7057276B2 (fr)
KR (2) KR20180053738A (fr)
CN (2) CN108368510B (fr)
AU (2) AU2016331819B2 (fr)
BR (2) BR112018006360A2 (fr)
CA (1) CA3000396A1 (fr)
CL (1) CL2018000833A1 (fr)
CO (1) CO2018003436A2 (fr)
CR (1) CR20180177A (fr)
EA (1) EA037882B1 (fr)
EC (1) ECSP18033227A (fr)
ES (1) ES2906823T3 (fr)
IL (1) IL258268B (fr)
MA (2) MA43053A (fr)
MX (1) MX2018003905A (fr)
MY (1) MY196646A (fr)
NI (1) NI201800044A (fr)
PE (1) PE20181367A1 (fr)
PH (1) PH12018500684A1 (fr)
SV (1) SV2018005659A (fr)
WO (2) WO2017059243A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190048089A1 (en) * 2015-09-30 2019-02-14 Janssen Biotech, Inc. Antagonistic Antibodies Specifically Binding Human CD40 and Methods of Use
CA3026880A1 (fr) 2016-06-08 2017-12-14 Xencor, Inc. Traitement des maladies associees aux igg4 par des anticorps anti-cd19 se reticulant a cd32b
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
EP3589324A1 (fr) * 2017-03-03 2020-01-08 Janssen Biotech, Inc. Co-thérapie comprenant un inhibiteur de csf-1r à petite molécule et un anticorps agoniste qui se lie spécifiquement au cd40 pour le traitement du cancer
EP3630832A1 (fr) * 2017-05-25 2020-04-08 Bristol-Myers Squibb Company Domaines fc d'igg1 modifiés et fusions d'anticorps de domaine anti-cd40 avec ces derniers
JP7257335B2 (ja) * 2017-05-25 2023-04-13 ブリストル－マイヤーズ スクイブ カンパニー アンタゴニスト性ｃｄ４０モノクローナル抗体およびその使用
US12296012B2 (en) 2017-06-02 2025-05-13 Pfizer Inc. Chimeric antigen receptors targeting FLT3
SG11202002366VA (en) * 2017-09-19 2020-04-29 Mab Discovery Gmbh Agonistic cd40 antibodies
KR20200074993A (ko) 2017-11-03 2020-06-25 노파르티스 아게 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
CN113728008B (zh) * 2019-04-10 2024-04-09 南开大学 抗cd40抗体及其用途
AU2020405230A1 (en) 2019-12-20 2022-06-23 Amgen Inc. Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
WO2021195326A1 (fr) * 2020-03-26 2021-09-30 Vanderbilt University Anticorps monoclonaux humains dirigés contre le coronavirus du syndrome respiratoire aigu sévère 2 (sras-cov-2)
DK4045533T5 (da) 2020-03-26 2024-07-29 Univ Vanderbilt Humane monoklonale antistoffer mod svær akut respiratorisk syndrom-coronavirus 2 (sars-cov-2)
EP4142739A2 (fr) 2020-04-27 2023-03-08 Twist Bioscience Corporation Bibliothèques d'acides nucléiques variants de coronavirus
CN113861292A (zh) * 2020-06-30 2021-12-31 百奥泰生物制药股份有限公司 抗cd40抗体或抗原结合片段及其应用
CA3195020A1 (fr) * 2020-10-07 2022-04-14 Samuel GENIER Agents biotherapeutiques vivants secretant des bacteriophages synthetiques dans le traitement du cancer
WO2022133123A1 (fr) * 2020-12-16 2022-06-23 Memorial Sloan Kettering Cancer Center Molécules de liaison à cd40 et leurs utilisations
BR112023026111A2 (pt) * 2021-06-28 2024-03-05 Jiangsu Hengrui Pharmaceuticals Co Ltd Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo
US20250179196A1 (en) * 2021-07-30 2025-06-05 Janssen Biotech, Inc. Materials and methods of making or using il-23r binding proteins
WO2023020475A1 (fr) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Anticorps ciblant cd40 et leurs utilisations
AU2022332499A1 (en) * 2021-08-24 2024-03-21 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fap/cd40 binding molecule and medicinal use thereof
US20240398942A1 (en) * 2021-09-26 2024-12-05 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of anti-cd40 antibody
WO2024126750A1 (fr) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Méthodes de traitement du cancer
TW202430226A (zh) * 2022-12-28 2024-08-01 大陸商上海盛迪醫藥有限公司 抗cd40抗體藥物偶聯物、其製備方法及其醫藥用途

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709A (en) 1850-10-08 Chas S Gaylord Improved spring-grapple
US226A (en) 1837-06-03 Samuel goss
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5247069A (en) 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
WO1988001649A1 (fr) 1986-09-02 1988-03-10 Genex Corporation Molecules de liaison de chaines de polypeptide simples
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP0940468A1 (fr) 1991-06-14 1999-09-08 Genentech, Inc. Domaine variable d'un anticorps humanisé
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
EP0945465B1 (fr) * 1992-07-09 2006-09-13 Novartis Vaccines and Diagnostics, Inc. Anticorps monoclonaux antagonistes contre la molécule humaine CD40
EP1005870B1 (fr) 1992-11-13 2009-01-21 Biogen Idec Inc. Application thérapeutique d'anticorps chimériques et radio-marqués contre l'antigène à différentiation restreinte des lymphocytes B humains pour le traitement du lymphome des cellules B
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
FI961285L (fi) 1993-10-01 1996-03-20 Immunex Corp CD40:n vasta-aineita
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
EP1242438B1 (fr) 1999-12-29 2006-11-08 Immunogen, Inc. Agents cytotoxiques comprenant des doxorubicines et des daunorubicines modifiees et utilisation therapeutique de ceux-ci
CN100490895C (zh) 2000-02-01 2009-05-27 泛遗传学公司 结合cd40的apc激活分子
CA2399388A1 (fr) 2000-02-11 2001-08-16 Michael J. Lenardo Identification d'un nouveau domaine dans la famille des recepteurs du facteur de necrose tumorale mediant l'assemblage et la fonction du recepteur de pre-ligand
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
JP4202127B2 (ja) 2000-10-02 2008-12-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
CA2658221C (fr) 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anticorps monoclonal anti-cd40
EP1283053A1 (fr) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibiteurs de l'activité de HER3
WO2003029296A1 (fr) * 2001-10-02 2003-04-10 Chiron Corporation Anticorps humains diriges contre le cd40
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
EP1504098B2 (fr) 2002-05-17 2011-02-09 Alligator Bioscience AB Methode de developpement moleculaire in vitro d'une fonction de proteine
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
JPWO2005007800A1 (ja) * 2003-07-18 2007-04-12 持田製薬株式会社 抗血小板膜糖蛋白質ｖｉモノクローナル抗体
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US20050202531A1 (en) * 2003-11-03 2005-09-15 Compugen Ltd. CD40 splice variants, compositions for making and methods of using the same
SG148143A1 (en) * 2003-11-04 2008-12-31 Novartis Vaccines & Diagnostic Antagonist anti-cd40 monoclonal antibodies and methods for their use
DK1684805T3 (da) * 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
ES2397631T3 (es) * 2003-12-25 2013-03-08 Kyowa Hakko Kirin Co., Ltd. Mutante antagonista de anticuerpos ANTI-CD40
KR20070026522A (ko) 2004-04-27 2007-03-08 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 길항제 항-ｃｄ40 모노클론 항체 및 이들의 사용 방법
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
WO2006081139A2 (fr) * 2005-01-26 2006-08-03 Abgenix, Inc. Anticorps diriges contre interleukine-1 beta
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
CA2609269C (fr) 2005-05-26 2014-08-05 Seattle Genetics, Inc. Anticorps anti-cd40 humanises et procedes d'utilisation
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
CN101351478A (zh) * 2005-11-01 2009-01-21 诺华有限公司 抗cd40抗体的应用
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
US8945564B2 (en) * 2006-04-21 2015-02-03 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions
EP1854810A1 (fr) 2006-05-09 2007-11-14 PanGenetics B.V. Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12
EA018030B1 (ru) * 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
EP2035456A1 (fr) 2006-06-22 2009-03-18 Novo Nordisk A/S Production d'anticorps bispécifiques
US20090074711A1 (en) 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
CN102123712B (zh) * 2006-12-13 2014-03-19 默沙东公司 使用igf1r抑制剂治疗癌症的方法
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
EP2522718B1 (fr) * 2007-02-23 2014-03-26 Baylor Research Institute Applications thérapeutiques de l'activation de cellules présentant un antigène humain via dectin-1
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
WO2009018386A1 (fr) 2007-07-31 2009-02-05 Medimmune, Llc Protéines de liaison à épitope multispécifiques et leurs utilisations
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
WO2009094391A1 (fr) 2008-01-23 2009-07-30 Xencor, Inc. Anticorps dirigés contre cd40 optimisés et leurs procédés d'utilisation
WO2009111450A2 (fr) * 2008-03-03 2009-09-11 Dyax Corp. Protéines de liaison à la métalloprotéinase 9
WO2010045340A1 (fr) 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Procédés d’humanisation et de maturation d’affinité d’anticorps
JP5986382B2 (ja) 2009-03-10 2016-09-06 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗原提示細胞ターゲティング癌ワクチン
JP5694921B2 (ja) 2009-04-20 2015-04-01 協和発酵キリン株式会社 アミノ酸変異が導入されたＩｇＧ２を有する抗体
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
WO2011021146A1 (fr) * 2009-08-20 2011-02-24 Pfizer Inc. Anticorps contre l'ostéopontine
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
PT3178851T (pt) * 2010-03-31 2020-07-17 Boehringer Ingelheim Int Anticorpos anti-cd40
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
EP2656073A4 (fr) * 2010-12-20 2014-12-17 Univ Rockefeller Modulation d'anticorps agonistes anti-tnfr
EP2654780B1 (fr) 2010-12-23 2017-02-01 Janssen Biotech, Inc. Mutants fc actifs d'anticorps résistants à une protéase
EP3556774B1 (fr) 2011-03-11 2024-01-03 Beth Israel Deaconess Medical Center Inc. Anticorps anti-cd40 et leurs utilisations
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
WO2012149356A2 (fr) 2011-04-29 2012-11-01 Apexigen, Inc. Anticorps anti-cd40 et leurs procédés d'utilisation
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
SMT202000091T1 (it) * 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
AU2012332021B8 (en) 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
AU2012349735B2 (en) * 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
WO2013124297A1 (fr) * 2012-02-22 2013-08-29 U3 Pharma Gmbh Composition d'une protéine de liaison d'hb-egf et d'un inhibiteur de l'egfr
NZ629697A (en) 2012-03-15 2017-01-27 Janssen Biotech Inc Human anti-cd27 antibodies, methods and uses
US8781132B2 (en) * 2012-03-19 2014-07-15 Motorola Solutions, Inc. Method and device for managing encrypted group rekeying in a radio network link layer encryption system
US9179480B2 (en) 2012-07-24 2015-11-03 Telefonaktiebolaget L M Ericsson (Publ) Apparatus and method for dynamically selecting a random access response window value for use with random access procedures in a network
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
CN104918957B (zh) * 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
US20140161790A1 (en) * 2012-11-19 2014-06-12 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
EP4269602A3 (fr) 2012-12-14 2023-12-27 OmniAB, Inc. Polynucléotides codant pour des anticorps de rongeur ayant des idiotypes humains, et animaux les comprenant
US10329350B2 (en) * 2012-12-26 2019-06-25 Industrial Technology Research Institute Method for producing a multivalent fab fragment with collagen-like peptide
KR20240123420A (ko) 2013-01-10 2024-08-13 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
WO2014126254A1 (fr) * 2013-02-18 2014-08-21 協和発酵キリン株式会社 Vecteur d'expression de protéine de liaison à une membrane
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
GB201322583D0 (en) 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
KR101740030B1 (ko) * 2014-03-07 2017-05-29 사회복지법인 삼성생명공익재단 ScFv 항체 라이브러리, 이의 제조방법 및 이를 이용한 ScFv 항체 스크리닝 방법
EP3113796A1 (fr) * 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Procédé d'utilisation de polypeptides d'anticorps qui sont des antagonistes de cd40 pour traiter une affection intestinale inflammatoire (aii)
US20170233485A1 (en) 2014-08-18 2017-08-17 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
US20190048089A1 (en) * 2015-09-30 2019-02-14 Janssen Biotech, Inc. Antagonistic Antibodies Specifically Binding Human CD40 and Methods of Use

Also Published As

Publication number Publication date
AU2016329057A1 (en) 2018-04-12
KR20180053738A (ko) 2018-05-23
US20190048089A1 (en) 2019-02-14
CN108368510A (zh) 2018-08-03
EP3355921A2 (fr) 2018-08-08
EP3356532A2 (fr) 2018-08-08
EA037882B1 (ru) 2021-05-31
US20170088624A1 (en) 2017-03-30
WO2017059243A2 (fr) 2017-04-06
CN109069622A (zh) 2018-12-21
CO2018003436A2 (es) 2018-06-20
US10544229B2 (en) 2020-01-28
EA201890834A1 (ru) 2018-12-28
BR112018006251A2 (pt) 2018-10-16
WO2017059196A3 (fr) 2017-06-08
IL258268B (en) 2022-09-01
MA43053A (fr) 2018-08-08
CR20180177A (es) 2018-06-22
IL258268A (en) 2018-05-31
SV2018005659A (es) 2019-03-28
JP7057276B2 (ja) 2022-04-19
EP3355921A4 (fr) 2019-05-22
EP3356532B1 (fr) 2022-01-19
BR112018006360A2 (pt) 2018-10-09
JP2018529351A (ja) 2018-10-11
EP3356532A4 (fr) 2019-09-11
KR102770238B1 (ko) 2025-02-18
NI201800044A (es) 2018-08-24
KR20180054837A (ko) 2018-05-24
CA3000396A1 (fr) 2017-04-06
ECSP18033227A (es) 2018-05-31
MX2018003905A (es) 2018-09-06
CN108368510B (zh) 2023-09-01
WO2017059243A3 (fr) 2017-06-08
PH12018500684A1 (en) 2018-10-01
AU2016331819A1 (en) 2018-04-12
CA3000400A1 (fr) 2017-04-06
PE20181367A1 (es) 2018-08-27
WO2017059196A2 (fr) 2017-04-06
JP2018533360A (ja) 2018-11-15
AU2016331819B2 (en) 2023-08-24
CL2018000833A1 (es) 2019-02-22
ES2906823T3 (es) 2022-04-20
MY196646A (en) 2023-04-27

Similar Documents

Publication Publication Date Title
EP3356532A4 (fr) Anticorps agonistes se liant de manière spécifique au cd40 humain et procédés d'utilisation
FR22C1048I2 (fr) Anticorps anti-cd3 et méthodes d'utilisation
EP3383913A4 (fr) Anticorps ciblant la protéine de type récepteur fc 5 et procédés d'utilisation
MA44723A (fr) Anticorps agonistes se liant au cd40 humain et leurs utilisations
EP3500594A4 (fr) Anticorps, fragments de liaison, et procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
EP3383412A4 (fr) Anticorps spécifiques de la protéine pd-1 glycosylée et leurs procédés d'utilisation
EP2852404A4 (fr) ANTICORPS ET IMMUNOCONJUGUÉS ANTI-Ly6E ET PROCÉDÉS D'UTILISATION
EP3393536A4 (fr) Membrane placentaire décellularisée et ses procédés de préparation et d'utilisation
MA56165A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA44776A (fr) Anticorps anti-vista humain et leur utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA42979A (fr) Anticorps anti-age et procédés d'utilisation correspondants
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
EP2847223A4 (fr) Anticorps anti-b7-h6, protéines de fusion, et leurs procédés d'utilisation
EP2874642A4 (fr) Protéines et peptides anti-inflammatoires et leurs procédés de préparation et d'utilisation
EP2912178A4 (fr) Super-activateurs et procédés d'utilisation de ceux-ci
EP2920319A4 (fr) Enzymes spécifiques de site et procédés d'utilisation associés
EP2709647A4 (fr) Protéines membranaires hydrosolubles et leurs procédés de préparation et d'utilisation
EP2841093A4 (fr) Anticorps activables liant le récepteur du facteur de croissance épidermique et leurs procédés d'utilisation
EP2721063A4 (fr) Polypeptides liant pcsk9 et leurs procédés d'utilisation
EP3394098A4 (fr) Anticorps anti-myostatine et procédés d'utilisation
EP2673381A4 (fr) Biosondes et procédés d'utilisation de celles-ci